Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: Meta-analysis of 3 randomized, controlled clinical trials

Journal of Clinical Pharmacology

Volumn 50, Issue 3, 2010, Pages 293-310

  Ortega, Ignacio ^a   Perez Ruixo, Juan Jose ^a   Stuyckens, Kim ^a   Piotrovsky, Vladimir ^a   Vermeulen, An ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Disease progression; Effectiveness; Modeling; Olanzapine; Paliperidone

Indexed keywords

OLANZAPINE; PALIPERIDONE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG RELEASE; HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; ISOXAZOLES; MODELS, PSYCHOLOGICAL; PRINCIPAL COMPONENT ANALYSIS; PSYCHOMETRICS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 77649215203     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009346057     Document Type: Article

References (46)

1. Aleman A., Kahn RS, Selten JP Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003 ; 60: 565-571.
2. Surgeon General?s Office. Mental Health: A Report of the Surgeon General, Table 2-6. 1997. http://www.surgeongeneral.gov=library=mentalhealth=toc.html. Accessed November 2006.
3. Goldner EM, Hsu L., Waraich P., et al. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry. 2002 ; 47: 833-843.
4. Freedman R. Schizophrenia. N Engl J Med. 2003 ; 349: 1738-1749.
5. Revicki DA, Shakespeare A., Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol. 1996 ; 11: 101-108.
6. Perlick DA, Rosenheck RA, Clarkin JF, et al. Symptoms predicting inpatient service use among patients with bipolar affective disorder. Psychiatr Serv. 1999 ; 50: 806-812.
7. Kay SR, Fiszbein A., Opler LA The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276.
8. European Medicines Agency (EMEA). Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia. London, UK: EMEA ; 1998. http://www.emea.europa.eu/pdfs/human/ewp/055995en.pdf. Accessed November 2006.
9. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002 ; 63: 763-771.
10. McEvoy JP Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatry. 1994 ; 55: 18-21.
11. Kapur S., Mizrahi R., Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 2005 ; 79: 59-68.
12. Karlsson P., Dencker E., Nyberg S., et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol. 2005 ; 15: S385.
13. Ereshefsky L., Mascarenas CA Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003 ; 64: 18-23.
14. Kapur S., Zipursky R., Jones C., et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000 ; 157: 514-520.
15. Kane J., Kramer M., Ford L., et al. Patients with acute schizophrenia: treatment with three fixed dosages of oral paliperidone extended-release tablets in a 6-week placebo-controlled study. Schizophr Res. 2007 ; 90: 147-161.
16. Marder S., Kramer M., Ford L., et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007 ; 62: 1363-1370.
17. Davidson M., Emsley R., Kramer M., et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized placebo-controlled study. Schizophr Res. 2007 ; 93: 117-130.
18. Beasley CM Jr, Sanger T., Satterlee W., et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996 ; 124: 159-167.
19. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999 ; 8: 417-426.
20. Chan PL, Holford NH Drug treatment effects on disease progression. Ann Rev Pharmacol Toxicol. 2001 ; 41: 625-659.
21. Piotrovsky V. Drug efficacy analysis as an exercise in dynamic (indirect-response) population PK-PD modelling. Abstracts of the Annual Meeting of the Population Approach Group in Europe 2002. www.page-meeting.org/?abstract= 305. Abstract 305 ; 11.
22. Post TM, Freijer JI, DeJongh J., et al. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res. 2005 ; 22: 1038-1049.
23. Yao Z., Krzyzanski W., Jusko WJ Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn. 2006 ; 33: 167-193.
24. Zyprexa (Eli Lilly) Olanzapine Tablets, ZYPREXA ZYDIS Olanzapine Orally Disintegrating Tablets, ZYPREXA IntraMuscular Olanzapine for Injection [package insert]. Indianapolis, IN: Eli Lilly and Company ; May 13, 2004.
25. Beal SL, Sheiner LB. eds. NONMEM Users Guides. Ellicot City, MD: Icon Development Solutions ; 1989-1998.
26. Hogan JW, Roy J., Korkontzelou C. Handling drop-out in longitudinal studies. Stat Med. 2004 ; 23: 1455-1497.
27. Efron B., Tibshirani R. An Introduction to the Bootstrap. London, UK: Chapman & Hall; 1993.
28. Yano Y., Beal SL, Sheiner LB Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001 ; 28: 171-192.
29. Piotrovsky V. Indirect-response model for the analysis of concentration-effect relationships in clinical trials where response variables are scores. Abstracts of the Annual Meeting of the Population Approach Group in Europe 2005. www.page-meeting.org/?abstract=773. Abstract 773 ; 14.
30. Welge JA, Keck PE Jr. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology. 2003 ; 166: 1-10.
31. Ruskin PE, Nyman G. Discontinuation of neuroleptic medication in older, outpatient schizophrenics. J Nerv Ment Dis. 1991 ; 1979: 212-214.
32. van de Laar N., Henter I., Bartko JJ, et al. Adverse events during a placebo phase for inpatients with chronic schizophrenia. Biol Psychiatry. 2001 ; 50: 487-492.
33. Wyatt RJ, Henter ID, Bartko JJ The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry. 1999 ; 46: 1092-1105.
34. Bhana N., Foster RH, Olney R., et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001 ; 61: 111-161. (Pubitemid 32108327)
35. Agid O., Seeman P., Kapur S. The "delayed onset" of antipsychotic action: an idea whose time has come and gone. J Psychiatry Neurosci. 2006 ; 31: 93-100.
36. Kapur S., Arenovich T., Agid O., et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005 ; 162: 939-946.
37. Farde L., Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992 ; 49: 538-544.
38. Kapur S., Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999 ; 156: 286-293.
39. Rubin DB Inferences and missing data. Biometrika. 1976 ; 63: 581-590.
40. Wahlbeck K., Tuunainen A., Ahokas A., et al. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl). 2001 ; 155: 230-233.
41. Storosum JG, Elferink AJ, van Zwieten BJ Schizophrenia: do we really need placebo-controlled studies ? Eur Neuropsychopharmacol. 1998 ; 8: 279-286.
42. Liu-Seifert H., Adas DH, Kinon BJ Discontinuation of treatment of schizophrenic patients is driven by poor symptoms response: a pooled post-hoc analysis of four atypical antipsychotic drug. BMC Med. 2005 ; 3: 21.
43. Hu C., Sale ME A joint model for nonlinear longitudinal data with informative drop-out. J Pharmacokin Pharmacodyn. 2003 ; 30: 83-103.
44. Raedler TJ, Schreiner A., Naber D., et al. Gender-specific effects in the treatment of acute schizophrenia with risperidone. Pharmacopsychiatry. 2006 ; 39: 171-174. (Pubitemid 44369176)
45. Frackiewicz EJ, Sramek JJ, Herrera JM, et al. Ethnicity and antipsychotic response. Ann Pharmacother. 1997 ; 31: 1360-1369.
46. Kimko HC, Reele SS, Holford NH, et al. Prediction of the outcome of a phase III clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther. 2000 ; 68: 568-577.